Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme/Third Wave

This article was originally published in The Gray Sheet

Executive Summary

Firms form preferred marketing relationship for Third Wave's Invader UGT1A1 molecular assay, which assesses the potential of adverse reactions to the chemotherapy drug Camptosar (Pfizer) for colorectal cancer. The test was 510(k)-cleared in August (1"The Gray Sheet" Aug. 29, 2005, p. 26). Genzyme announced exclusive diagnostic rights to the UCLA Jonsson Cancer Center's discovery of gene mutations associated with drug resistance to Novartis' Gleevec, used to treat chronic myeloid leukemia, Oct. 6...

You may also be interested in...

FDA Clears Third Wave Invader Pharmacogenetic Test

Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?

UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit

Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts